文献类型：期刊文献

英文题名：Salvia miltiorrhiza Bunge root in the treatment of myocardial fibrosis: research progress and challenges

作者：Li, Qianrong[1,2,3];Ren, Chunzhen[1,2,3];Jiang, Bing[1,2,3];Wang, Xuehan[2,3,4];Wang, Chunling[1,2,3];Zhi, Xiaodong[1,2,3,5];Li, Linchan[1,2,3,6];Guo, Xiaoying[1,2,3];Zhao, Xinke[1,2,3,5];Li, Yingdong[1,2,3]

第一作者：Li, Qianrong

通信作者：Zhao, XK[1];Li, YD[1];Zhao, XK[2];Li, YD[2];Zhao, XK[3];Li, YD[3];Zhao, XK[4]

机构：[1]Gansu Univ Chinese Med, Sch Tradit Chinese & Western Med, Lanzhou, Peoples R China;[2]Gansu Univ Chinese Med, Coll Integrated Tradit Chinese & Western Med, Gansu Prov Key Lab Chinese Med Prevent & Treatment, Lanzhou, Peoples R China;[3]Key Specialized Cardiovasc Lab Natl Adm Tradit Chi, Key Clin Specialty Natl Hlth Commiss Peoples Repub, Lanzhou, Peoples R China;[4]Lanzhou Univ, Clin Med Coll 1, Lanzhou, Peoples R China;[5]Gansu Univ Chinese Med, Affiliated Hosp, Lanzhou, Peoples R China;[6]Shaanxi Prov Hosp Chinese Med, Oncol Dept, Xian, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Sch Tradit Chinese & Western Med, Lanzhou, Peoples R China;[2]corresponding author), Gansu Univ Chinese Med, Coll Integrated Tradit Chinese & Western Med, Gansu Prov Key Lab Chinese Med Prevent & Treatment, Lanzhou, Peoples R China;[3]corresponding author), Key Specialized Cardiovasc Lab Natl Adm Tradit Chi, Key Clin Specialty Natl Hlth Commiss Peoples Repub, Lanzhou, Peoples R China;[4]corresponding author), Gansu Univ Chinese Med, Affiliated Hosp, Lanzhou, Peoples R China.|[10735b845793de6ae2b30]甘肃中医药大学第二附属医院;[10735]甘肃中医药大学;[10735ed249c6606940a33]甘肃中医药大学中西医结合学院;

年份：2025

卷号：16

外文期刊名：FRONTIERS IN PHARMACOLOGY

收录：;Scopus(收录号：2-s2.0-105002482217);WOS:【SCI-EXPANDED(收录号:WOS:001465807400001)】；

基金：The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the Gansu Jiaoyu Jiebang Guashuai Project (No. 2021 jyjbgs-03), National Natural Science Foundation of China (No. 82360926, 82374279), Gansu Province Dual Top-class Scientific Research Key Project (GSSYLXM-05), Gansu Provincial Science and Technology Major Project (No. 20ZD7FA002), Gansu Provincial University Teachers' Innovation Fund Project in 2025 (No. 2025B-126), 2024 Gansu Province Outstanding Doctoral Project (24JRRA569).

语种：英文

外文关键词：natural medicine Salvia miltiorrhiza Bunge; MF; advancements in research; metabolites; pharmacological mechanism

摘要：Myocardial fibrosis (MF) involves the activation and excessive proliferation of cardiac fibroblasts (CFs) in the extracellular matrix, leading to increased collagen expression that impairs cardiac function. Currently, there are no effective pharmacological treatments for MF. Traditional Chinese Medicine (TCM), particularly Salvia miltiorrhiza Bunge [Lamiaceae; Salviae miltiorrhizae radix et rhizoma], has gained attention for its potential in treating MF. Recent studies indicate significant therapeutic effects of its active metabolites, supporting its use in MF treatment and positioning it as a promising candidate for drug development. Aim of the review: This article reviews the research and mechanisms of S. miltiorrhiza's effective metabolites and preparations in treating MF, providing a reference for future clinical treatments. A systematic literature search was conducted in PubMed, Web of Science, CNKI, and Google Scholar (January 2000-October 2024) using keywords: "myocardial fibrosis," "cardiac fibrosis," "Salvia miltiorrhiza Bunge," "extract," and "botanical drug." Results: The active metabolites of S. miltiorrhiza and its metabolite preparations exert anti-fibrotic effects through pleiotropic mechanisms, including suppression of ventricular remodeling, modulation of autophagy, inhibition of oxidative stress and cardiomyocyte apoptosis, and regulation of extracellular matrix homeostasis and immune-inflammatory responses. Conclusion: Research indicates that S. miltiorrhiza is beneficial for managing MF, but further studies are needed to identify its chemical metabolites and regulatory mechanisms. Large-scale, multi-center clinical trials are also necessary to assess treatment safety. This review offers insights for developing new anti-MF pharmacotherapies.